ManufacturingWith a $70 million expansion in Massachusetts, AbbVie plans...
Manufacturing

With a $70 million expansion in Massachusetts, AbbVie plans the next phase of its US investment adventure

Editotial Team
By Editotial Team

-

1025
0

No content provided.

e8ca33a26f7037921e92de08cb2a519d8f9a37c9966383abf07edbf18b55cb25?s=150&d=mp&r=g
+ posts
Previous article
Rocket abandons its attempt to obtain FDA approval for bone marrow gene therapy
Next article
Aerska Launches with $21 Million to Develop RNAi Medicines for Neurological Diseases
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team
Editotial Team

Latest news

Regulatory

GSK’s Hepatitis B Drug Gets FDA Green Light

GSK has secured U.S. approval for bepirovirsen, an antisense oligonucleotide licensed from Ionis Pharmaceuticals, marking a milestone in the...
Insights

Real-Time Commercial Intelligence in Life Sciences

Executive Summary Pharmaceutical commercial teams are operating in markets where competitive activity, treatment preferences, access conditions, and customer expectations can...
Insights

Top 10 AI Skills Every Life Sciences Leader Needs

Executive Summary Artificial intelligence is reshaping drug discovery, clinical development, manufacturing, regulatory operations, and Medical Affairs. As adoption expands, life...

Must read

Commercial

Commercial Excellence Summit Brings Together Leading Minds to Solve Critical Commercial Problems

This week is set to be a pivotal one...
Commercial

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you